news

CUPERTINO, Calif., Feb. 9, 2011 /PRNewswire via COMTEX/ — DURECT Corporation (Nasdaq: DRRX) announced today results from a European Phase IIb shoulder clinical trial conducted by Nycomed of POSIDUR(TM) (also known as SABER(TM)-bupivacaine or Optesia(TM) in the E.U.), a proprietary product under development for the treatment of post-surgical pain, and the amendment of the Company’s […]

Covers an Animal Health Application CUPERTINO, Calif., Feb. 8, 2011 /PRNewswire via COMTEX/ — DURECT Corporation (Nasdaq: DRRX) today reported that its collaborator, CreoSalus, Inc., has launched commercial sales of its Food and Drug Administration (FDA) approved product known as SucroMate(TM) Equine, an injectable animal health drug utilizing DURECT’s SABER(TM) technology to deliver the peptide

CUPERTINO, Calif., Feb. 7, 2011 /PRNewswire via COMTEX/ — DURECT Corporation (Nasdaq: DRRX) announced today that Matt Hogan (Chief Financial Officer) will be presenting at the BIO CEO & Investor Conference on Monday, February 14 at 9:30 a.m. Eastern Time. The conference is being held at the Waldorf-Astoria Hotel in New York City. (Logo: http://photos.prnewswire.com/prnh/20020717/DRRXLOGO)

CUPERTINO, Calif., Jan. 27, 2011 /PRNewswire via COMTEX/ — DURECT Corporation (Nasdaq: DRRX) today reported that the U.S. Food and Drug Administration (FDA) has accepted the resubmission of the New Drug Application (NDA) for REMOXY(R) by King Pharmaceuticals, Inc. (NYSE: KG) and the PDUFA goal date is June 23, 2011. (Logo: http://photos.prnewswire.com/prnh/20020717/DRRXLOGO) REMOXY, based on

CUPERTINO, Calif., Dec. 27, 2010 /PRNewswire via COMTEX/ — DURECT Corporation (Nasdaq: DRRX) today reported that King Pharmaceuticals, Inc. (NYSE: KG) and Pain Therapeutics, Inc. (Nasdaq: PTIE) have announced that King has resubmitted a New Drug Application (NDA) for REMOXY(R) to the U.S. Food and Drug Administration (FDA) in response to a Complete Response Letter

CUPERTINO, Calif., Nov. 22, 2010 /PRNewswire via COMTEX/ — DURECT Corporation (Nasdaq: DRRX) announced today that Matt Hogan (Chief Financial Officer) and Joe Stauffer (Chief Medical Officer) will be presenting at the 22nd Annual Piper Jaffray Health Care Conference on Wednesday, December 1 at 10:30 a.m. Eastern Time. The conference is being held at the

CUPERTINO, Calif., Nov. 8, 2010 /PRNewswire via COMTEX/ — DURECT Corporation (Nasdaq: DRRX) announced today that James E. Brown, President and CEO, will be presenting at the Credit Suisse 2010 Healthcare Conference on Friday, November 12 at 8:30 a.m. Pacific Time. The conference is being held at the Arizona Biltmore in Phoenix. (Logo: http://photos.prnewswire.com/prnh/20020717/DRRXLOGO) (Logo:

CUPERTINO, Calif., Nov. 3, 2010 /PRNewswire via COMTEX/ — DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months ended September 30, 2010. Total revenues were $8.1 million for the three months ended September 30, 2010 compared to $8.4 million for the three months ended September 30, 2009; revenues in the 2009 period

CUPERTINO, Calif., Nov. 2, 2010 /PRNewswire via COMTEX/ — DURECT Corporation (Nasdaq: DRRX) announced today that it has been awarded grants totaling $733,438 to advance our programs in post-operative pain relief, attention deficit disorder (ADHD) and chronic diseases treated with biologic agents. The grants are being awarded under the Patient Protection and Affordable Care Act

CUPERTINO, Calif., Oct 27, 2010 /PRNewswire via COMTEX/ — In conjunction with DURECT Corporation’s (Nasdaq: DRRX) third quarter 2010 financial results press release, you are invited to listen to the conference call that will be broadcast live over the internet on Wednesday, November 3, 2010 at 4:30 pm Eastern Time (1:30 pm Pacific Time). (Logo: